Home › Funds › BECK MACK & OLIVER LLC › ABT

BECK MACK & OLIVER LLC position in ABT

ABBOTT LABORATORIES · Health Care

BECK MACK & OLIVER LLC reported holding 1,123,527 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$101.9M, representing 2.15% of its reported portfolio and ranking #17 among its reported holdings. BECK MACK & OLIVER LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.12M sh
Reported value held$101.95M
Portfolio Weight2.15%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BECK MACK & OLIVER LLC's ABT position evolved

BECK MACK & OLIVER LLC first disclosed a stake in ABT in Q3 2023 at 776,115 shares (US$75.2M). The position peaked in Q3 2025 at 864,174 shares, worth US$115.7M. Across 12 filings, BECK MACK & OLIVER LLC increased the stake 9 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,123,527 shares valued at US$101.9M — an increase of 188,100 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 776.12K $75.17M New
Q4 2023 789.71K $86.92M Add
Q1 2024 806.63K $91.68M Add
Q2 2024 790.91K $82.18M Reduce
Q3 2024 800.36K $91.25M Add
Q4 2024 810.46K $91.67M Add
Q1 2025 842.67K $111.78M Add
Q2 2025 846.40K $115.12M Hold
Q3 2025 864.17K $115.75M Add
Q4 2025 874.73K $109.59M Add
Q1 2026 935.43K $96.04M Add
Q2 2026 1.12M $101.95M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has BECK MACK & OLIVER LLC held ABT?

BECK MACK & OLIVER LLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BECK MACK & OLIVER LLC's current position in ABT?

As of Q2 2026, BECK MACK & OLIVER LLC holds 1.12M shares of ABT (ABBOTT LABORATORIES), valued at $101.95M, representing 2.15% of its reported portfolio and ranking #17.

Has BECK MACK & OLIVER LLC been buying or selling ABT?

In the latest 13F filing (Q2 2026), BECK MACK & OLIVER LLC increased its position in ABT. The position peaked in Q3 2025 at 864.17K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.